Tofersen: First Approval
This article summarizes the milestones in the development of tofersen leading to this first approval for ALS. (Source: Drugs)
Source: Drugs - June 15, 2023 Category: Drugs & Pharmacology Source Type: research
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
AbstractFenfluramine (Fintepla®) is an oral anti-seizure medication (ASM) with a novel mechanism of action consisting of activity in the serotonergic system coupled with positive allosteric modulation effects at sigma-1 receptors. Originally approved for use at high doses as an appetite suppressant, it was subsequently withdrawn after being linked to valvular heart disease (VHD) and pulmonary arterial hypertension (PAH), before being investigated for use at low doses as an adjunctive ASM in patients with developmental epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) who have pha...
Source: Drugs - June 15, 2023 Category: Drugs & Pharmacology Source Type: research
Tofersen: First Approval
This article summarizes the milestones in the development of tofersen leading to this first approval for ALS. (Source: Drugs)
Source: Drugs - June 15, 2023 Category: Drugs & Pharmacology Source Type: research
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review
AbstractConsolidated data from pharmacokinetic and pharmacodynamic studies support the administration of β-lactam antibiotics in prolonged infusion (i.e., extended or continuous) to optimize therapeutic efficacy by increasing the probability of attaining maximal bactericidal activity. This is the longest possible time during which the free drug concentrations are approximately four-fold the minimum in hibitory concentration between dosing intervals. In the context of antimicrobial stewardship strategies, achieving aggressive pharmacokinetic and pharmacodynamic targets is an important tool in the management of multi-drug r...
Source: Drugs - June 14, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Lenacapavir: First Approval
(Source: Drugs)
Source: Drugs - June 14, 2023 Category: Drugs & Pharmacology Source Type: research
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review
AbstractConsolidated data from pharmacokinetic and pharmacodynamic studies support the administration of β-lactam antibiotics in prolonged infusion (i.e., extended or continuous) to optimize therapeutic efficacy by increasing the probability of attaining maximal bactericidal activity. This is the longest possible time during which the free drug concentrations are approximately four-fold the minimum in hibitory concentration between dosing intervals. In the context of antimicrobial stewardship strategies, achieving aggressive pharmacokinetic and pharmacodynamic targets is an important tool in the management of multi-drug r...
Source: Drugs - June 14, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Lenacapavir: First Approval
(Source: Drugs)
Source: Drugs - June 14, 2023 Category: Drugs & Pharmacology Source Type: research
Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature
AbstractIntravenous methadone may be useful in acute and chronic pain management compared with other opioids because of its pharmacokinetic and pharmacodynamic characteristics, including the long duration of effect and ability to modulate both pain stimuli propagation and analgesic descending pathways. However, methadone is underused in pain medicine because of several misperceptions. A review of studies was performed to assess data regarding the use of methadone in perioperative pain and chronic cancer pain. The majority of studies have shown that intravenous methadone produces an effective postoperative analgesia and low...
Source: Drugs - June 13, 2023 Category: Drugs & Pharmacology Source Type: research
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
AbstractA growing number of clinical trials are documenting that adding a long-acting muscarinic antagonist (LAMA) to established asthma treatment with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) is a treatment option that improves the health of patients with uncontrolled severe asthma even when therapy is optimized. These favorable results are the reason why the leading guidelines recommend triple therapy with ICS + LABA + LAMA in patients with asthma uncontrolled by medium- to high-dose ICS-LABA. However, we suggest adding LAMAs to ICS-LABAs at an earlier clinical stage. Such action could posit...
Source: Drugs - June 12, 2023 Category: Drugs & Pharmacology Source Type: research
Glofitamab: First Approval
This article summarizes the milestones in the development of glofitamab leading to this first approval for relapsed or refractory DLBCL. (Source: Drugs)
Source: Drugs - June 7, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Sparsentan: First Approval
(Source: Drugs)
Source: Drugs - June 6, 2023 Category: Drugs & Pharmacology Source Type: research
